Biota Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. The Company has around four product candidates in clinical development that address viral infections that have limited therapeutic options. Its product candidates include vapendavir, which is an oral treatment for human rhinovirus (HRV) infections in moderate-to-severe asthmatics that is being evaluated in its ongoing Phase IIb SPIRITUS trial; BTA074, a Phase II topical antiviral treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA585, an oral fusion (F) protein inhibitor in Phase I development for the treatment of respiratory syncytial virus (RSV)-A and RSV-B infections, and laninamivir octanoate, a one-time, inhaled treatment in Phase II development for influenza A and B infections. The Company also has preclinical RSV non-fusion inhibitor program.